All Posts

Marstacimab Anti-TFPI Moab Submitted for FDA and EMA Approval

Pfizer has applied to the US FDA and the European Medicines Agency [EMA] for approval of their monoclonal antibody anti-tissue factor pathway inhibitor [TFPI] therapeutic, marsticimab, a competitor to Novo Nordisk’s concizumab, approved by Health Canada under the trademark Alhemo®, and awaiting FDA and EMA approval. The FDA anticipates an FDA ruling in the fourth […]

Bleeding Disorders

Clot Detection by Wooden Sticks

Fritsma Factor participants, a colleague brought up the problem of clotted hemostasis specimens within the context of remote specimen collection. Many facilities recommend checking whole blood specimens with wooden sticks, a policy that has been in place since before 1990 but raises concern for contamination, clot activation, and operator safety. The broad availability of automation […]

Specimen Management

PBI Webinar: FVIII & FIX Testing of Emerging Therapies

I (Geo) recommend a May 8, 2024 Precision BioLogic webinar by Chief Scientific Officer Jon Geske, PhD and Marketing Director Ian Burns that compares one-stage clot-based and chromogenic assays when testing for the activity of extended half-life FVIII and FIX concentrates, FVIII mimetics such as emicizumab, RNAi‘s such as fitusiran, and the products of FVIII […]

Bleeding Disorders

Is DRVVT Normalization Necessary?

The clot-based dilute Russell viper venom test (DRVVT) reagent activates the coagulation mechanism’s common pathway at the factor X (10) level, relying only on factor V, prothrombin, and fibrinogen for clot formation. The DRVVT test complements the PTT-based assay for lupus anticoagulant (LAC) detection. Because LAC is phospholipid (PL)-dependent, both assays use a minimal-phospholipid (PL) […]

May 2024 Cheat Sheet

Here’s your May 2024 Cheat Sheet recounting several April posts and events. If you want to receive our Cheat Sheet in your email, click “Cheat Sheets from George” and provide your first and last name. Like Fritsma Factor, Cheat Sheets are free, and subscribing does not expose you to marketing materials.

May 2024: QQ Poll: Trigger Point for PLT Concentrate Therapy

Our May 2024 Quick Question asks, “Below what PLT count limit do you provide PLT concentrate?” Please show us your facility’s PLT count limit and add a comment below or using the Questions or Comments box.

Bleeding Disorders

April 2024 QQ Summary: MYH9 Mutation

Our April 2024 Quick Question, “What PLT production abnormality is an MYH9 gene mutation?” attracted 26 responses. Here’s the distribution: Thrombocytopenia with absent radii [TAR]: 4 [15%] Bernard-Soulier syndrome [BSS]: 2 [7%] Immune thrombocytopenia [ITP]: 1 [4%] Wiskott-Aldrich syndrome: 1 [4%] May-Hegglin disorder: 18 [70%] The production abnormalities are associated with mild to severe bleeding. […]

Bleeding Disorders

Testing for the Lupus Anticoagulant: The Good, the Bad, and the Ugly

Click here for a “State of the Art Review,” Favaloro EJ, Pasalic L, Selby R. Testing for the lupus anticoagulant: The good, the bad, and the ugly. Research and Practice in Thrombosis and Haemostasis 2024; 8: DOI:https://doi.org/10.1016/j.rpth.2024.102385.

VWD Diagnosis and Monitoring Update

Dr. Annette Bowyer posted this open-access publication today, 3-3-24 on LinkedIn: Platton S, Baker P, Bowyer A, et al. Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors’ Organisation and the British Society for Haematology. Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19385. Epub […]

Bleeding Disorders

April 2024 Cheat Sheet

Click here for your April 2024 Cheat Sheet or watch for your copy by email.

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question